Long-term contraception with Depo-Provera: a clinical evaluation.
Depo-Provera has been used as a long-acting injectable contraceptive. The results of the study carried out for more than 2 years indicate that the depot formulation of medroxyprogesterone acetate (DMPA, Depo-Provera) at a dose of 150 mg at 90-day intervals appears to be acceptable to some women of this part of India, though many of them experience menstrual problems. However, irregular and/or excessive menstrual bleeding diminishes with long-term use of the contraceptive and a high percentage of users become amenorrheic. No major adverse reactions were observed and the minor side effects are comparable to those reported for the oral contraceptives. There was a tendency for weight-gain by the patients and the endometrium became atrophic or "resting" with the prolongation of the therapy.
D000293:Adolescent; D000328:Adult; D001835:Body Weight / Q000187:drug effects; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D008598:Menstruation / Q000187:drug effects
D003692:Delayed-Action Preparations; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone